Kidney Week

Abstract: FR-PO1106

The Risk of ESRD in Systemic Lupus Erythematosus: A Nationwide Population-Based Study in Korea

Session Information

• Glomerular Diseases: Clinical, Outcomes, Trials - II
  October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

• Choi, Hong sang, Chonnam National University Medical School, Gwangju, Korea (the Republic of)

Hong sang Choi,

• Kim, Chang Seong, Chonnam National University Medical School, Gwangju, Korea (the Republic of)

Chang Seong Kim,

• Bae, Eun Hui, Chonnam National University Medical School, Gwangju, Korea (the Republic of)

Eun Hui Bae,

• Ma, Seong Kwon, Chonnam National University Medical School, Gwangju, Korea (the Republic of)

Seong Kwon Ma,

• Kim, Soo Wan, Chonnam National University Medical School, Gwangju, Korea (the Republic of)

Soo Wan Kim,

Background

SLE is known to be one of the leading cause of end-stage renal disease (ESRD). The aim of this study was to estimate the incidence rate of ESRD and the risk factors for progression to ESRD in SLE patients compared to general population.

Methods

21,253 SLE patients (mean age, 41.91±13.22 years; female, 90.4%) were extracted from the Korean National Health Insurance Service database between 2008 and 2014. Age-and sex-matched controls (n=106,265) were randomly sampled in a 5:1 ratio from non-SLE individuals. Both cohorts were followed up for incident ESRD until 2015.

Results

During the total 8 years of follow-up, 145 (0.14%) cases of ESRD was newly developed in SLE patients and 533 (2.51%) cases in matched controls (incidence: 4.075 and 0.219 per 1000 person-year, respectively). SLE patients were at higher risk for ESRD development compared to matched controls (odd ratio (OR), 10.134; 95% confidence interval (CI) 8.368-12.343) after multivariate adjustment. In subgroup analysis, the risk for ESRD was higher in male with SLE (OR, 7.952; 95% CI 5.26-12.272), in female with SLE (OR, 10.82; 95% CI 8.719-13.526), in 20-39 year-old patients with SLE (OR, 22.57; 95% CI 14.588-36.449), in 40-64 year-old patients with SLE (OR, 22.57; 95% CI 14.588-36.449), in elder than 65 year-old patients with SLE (OR, 5.122; 95% CI 3.431-7.649) than matched control, respectively.

Conclusion

SLE was associated with an increasing incidence of ESRD